Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

Figure 1

Kinetic of MART-1-specific CD8 T-cell responses following immunization. A. Representative example of the increase in the frequency of circulating MART-1-specific CD8 T cells in Pt#1185 and Pt#1013 following infusion. MART-1-specific CD8 T cells are identified using peptide-MHC class I multimer complexes and plots are gated on viable CD3+CD8+ T cells. B. Prototypic examples of the kinetic of MART-1-specific CD8 T cells in patients from the IMP321 or no IMP321 groups. Dotted lines represent the initial frequency of MART-1-specific CD8 T cells prior to lymphodepletion. C. Proportion of patients from each group with a peak in the frequency of MART-1-specific CD8 T cells. Peaks were defined as a frequency of MART-1-specific CD8 T cells > three-fold higher than baseline, i.e. D-15 (n = 6 for each group, *P < 0.02). D. Cumulative analysis of the fold increase of MART-1-specific CD8 T cells overtime in the different groups. Mean + SEM are shown (n = 6 for each group, *P < 0.02).

Back to article page